Literature DB >> 29299828

Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer.

Katarzyna Starska1, Ewa Forma2, Iwona Lewy-Trenda3, Olga Stasikowska-Kanicka4, Michał Skóra5, Magdalena Bryś2.   

Abstract

PURPOSE: Aberrant fibroblast growth factor receptor (FGFR) expression is thought to contribute to the development of many types of cancer. As yet, however, their impact on the course and prognosis of head and neck cancer remains to be determined. Here, we aimed to investigate the effects of expression of the FGFR family members FGFR1 and FGFR3, as well as their downstream PI3K/AKT signal-regulated kinases, on the aggressiveness and prognosis of laryngeal cancer.
METHODS: In total 137 surgically removed squamous cell laryngeal cancer (SCLC) and 100 matched non-cancerous laryngeal mucosa (NCLM) samples were assessed for mRNA expression using quantitative real-time PCR. The corresponding proteins were analyzed by Western blotting. SLUG expression was assessed by immunohistochemistry. The expression data were subsequently related to tumor front grading (TFG), local/nodal recurrences, prognosis and overall survival.
RESULTS: The FGFR1, FGFR3 and PI3K/AKT kinase mRNA and protein levels were found to be significantly higher in the SCLC than the NCLM samples (p < 0.05). A high FGFR1 mRNA/protein expression level was found to be associated with an increased invasion rate, according to TFG scale and SLUG level, a high local/nodal recurrence rate and a poor prognosis (p < 0.05). Similarly, we found that a high FGFR3 mRNA/protein expression level was associated with a shorter survival time (p < 0.05). In addition, we found that high PI3K/AKT kinase mRNA/protein levels were associated with a high TFG (p < 0.05). We also found that FGFR1/3 mRNA and FGFR1 protein levels were inversely associated with overall survival (log-rank test: FGFR1 mRNA p = 0.03, FGFR3 mRNA p = 0.04, FGFR1 protein p = 0.03). Subsequent multivariate analyses revealed that high FGFR3 mRNA expression may serve as an independent poor prognostic factor (HR 2.32, 95% CI 1.03-6.59; p = 0.04). We also found that the p-PI3K regulatory kinase protein level was significantly associated with survival in the cohort studied (HR 1.78, 95% CI 0.64-8.53; p = 0.03).
CONCLUSIONS: From our data we conclude that FGFR1 and FGFR3, as well as its downstream regulatory PI3K/AKT kinases, may serve as potential biomarkers for the invasiveness and prognosis of laryngeal cancer. The expression of FGFR1/3-PI3K/AKT regulatory pathway members may be instrumental for the identification of patients at risk for an unfavorable clinical outcome.

Entities:  

Keywords:  FGFR1; FGFR3; Laryngeal cancer; Local/nodal recurrences; Overall survival; PI3K/AKT; Slug; Tumor front grading

Mesh:

Substances:

Year:  2018        PMID: 29299828     DOI: 10.1007/s13402-017-0367-z

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  48 in total

1.  PI3K Overexpression and PIK3CA Mutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma.

Authors:  Jing-Wei Lin; Xu Li; Ming-Lian Qiu; Rong-Gang Luo; Jian-Bo Lin; Bo Liu
Journal:  Genet Test Mol Biomarkers       Date:  2017-02-17

2.  Nicotine promotes cervical carcinoma cell line HeLa migration and invasion by activating PI3k/Akt/NF-κB pathway in vitro.

Authors:  Chengze Wang; Weiting Gu; Yunpeng Zhang; Yawen Ji; Yong Wen; Xin Xu
Journal:  Exp Toxicol Pathol       Date:  2017-04-03

Review 3.  Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.

Authors:  Cinta Hierro; Jordi Rodon; Josep Tabernero
Journal:  Semin Oncol       Date:  2015-09-24       Impact factor: 4.929

Review 4.  FGFR Signaling as a Target for Lung Cancer Therapy.

Authors:  Arpita Desai; Alex A Adjei
Journal:  J Thorac Oncol       Date:  2016-01       Impact factor: 15.609

Review 5.  FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).

Authors:  Masaru Katoh
Journal:  Int J Mol Med       Date:  2016-05-31       Impact factor: 4.101

6.  Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors.

Authors:  Jennifer J Wheler; Johnique T Atkins; Filip Janku; Stacy L Moulder; Philip J Stephens; Roman Yelensky; Vicente Valero; Vincent Miller; Razelle Kurzrock; Funda Meric-Bernstam
Journal:  Oncoscience       Date:  2016-06-30

7.  Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics.

Authors:  A Parish; M Schwaederle; G Daniels; D Piccioni; P Fanta; R Schwab; K Shimabukuro; B A Parker; T Helsten; R Kurzrock
Journal:  Cell Cycle       Date:  2015-05-07       Impact factor: 4.534

8.  Fibroblast growth factor receptor 1 promotes MG63 cell proliferation and is associated with increased expression of cyclin-dependent kinase 1 in osteosarcoma.

Authors:  Wei Zhou; Yue Zhu; Song Chen; Ruijun Xu; Kunzheng Wang
Journal:  Mol Med Rep       Date:  2015-11-23       Impact factor: 2.952

9.  Topoisomerase IIβ binding protein 1 c.*229C>T (rs115160714) gene polymorphism and endometrial cancer risk.

Authors:  Ewa Forma; Katarzyna Wójcik-Krowiranda; Paweł Jóźwiak; Agnieszka Szymczyk; Andrzej Bieńkiewicz; Magdalena Bryś; Anna Krześlak
Journal:  Pathol Oncol Res       Date:  2013-12-18       Impact factor: 3.201

Review 10.  The role of lymphangiogenesis and angiogenesis in tumor metastasis.

Authors:  Roman Paduch
Journal:  Cell Oncol (Dordr)       Date:  2016-04-28       Impact factor: 6.730

View more
  13 in total

1.  Human Papillomavirus 11 Early Protein E6 Activates Autophagy by Repressing AKT/mTOR and Erk/mTOR.

Authors:  Boya Zhang; Yinjing Song; Siyuan Sun; Rui Han; Chunting Hua; Stijn van der Veen; Hao Cheng
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

2.  Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer.

Authors:  Zechen Wang; Karen S Anderson
Journal:  Cancer J       Date:  2022 Sep-Oct 01       Impact factor: 2.074

3.  Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.

Authors:  Sylvia Grünewald; Oliver Politz; Sebastian Bender; Mélanie Héroult; Klemens Lustig; Uwe Thuss; Christoph Kneip; Charlotte Kopitz; Dieter Zopf; Marie-Pierre Collin; Ulf Boemer; Stuart Ince; Peter Ellinghaus; Dominik Mumberg; Holger Hess-Stumpp; Karl Ziegelbauer
Journal:  Int J Cancer       Date:  2019-03-13       Impact factor: 7.396

4.  ESRRG promoter hypermethylation as a diagnostic and prognostic biomarker in laryngeal squamous cell carcinoma.

Authors:  Zhisen Shen; Yan Hu; Chongchang Zhou; Jie Yuan; Jie Xu; Wenjuan Hao; Hongxia Deng; Dong Ye
Journal:  J Clin Lab Anal       Date:  2019-04-19       Impact factor: 2.352

5.  Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patients.

Authors:  Laura Pena-Couso; María Ercibengoa; Fátima Mercadillo; David Gómez-Sánchez; Lucía Inglada-Pérez; María Santos; Javier Lanillos; David Gutiérrez-Abad; Almudena Hernández; Pablo Carbonell; Rocío Letón; Mercedes Robledo; Cristina Rodríguez-Antona; José Perea; Miguel Urioste
Journal:  Orphanet J Rare Dis       Date:  2022-02-28       Impact factor: 4.123

Review 6.  Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression.

Authors:  Chen Xue; Ganglei Li; Juan Lu; Lanjuan Li
Journal:  Signal Transduct Target Ther       Date:  2021-11-24

Review 7.  Role of PI3K/AKT pathway in squamous cell carcinoma with an especial focus on head and neck cancers.

Authors:  Soudeh Ghafouri-Fard; Ali Noie Alamdari; Yashar Noee Alamdari; Atefe Abak; Bashdar Mahmud Hussen; Mohammad Taheri; Elena Jamali
Journal:  Cancer Cell Int       Date:  2022-08-13       Impact factor: 6.429

8.  Overexpression of glycosyltransferase 8 domain containing 2 confers ovarian cancer to CDDP resistance by activating FGFR/PI3K signalling axis.

Authors:  Shuting Huang; Suiying Liang; Guandi Chen; Jing Chen; Keli You; Haiyan Ye; Zhigang Li; Shanyang He
Journal:  Oncogenesis       Date:  2021-07-22       Impact factor: 7.485

9.  Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients.

Authors:  Lu Chen; Huijie Qi; Liudi Zhang; Haixia Li; Jie Shao; Haifei Chen; Mingkang Zhong; Xiaojin Shi; Ting Ye; Qunyi Li
Journal:  BMC Cancer       Date:  2018-10-25       Impact factor: 4.430

10.  Long Non-Coding RNA PART1 Exerts Tumor Suppressive Functions in Glioma via Sponging miR-190a-3p and Inactivation of PTEN/AKT Pathway.

Authors:  Zheng Jin; Lianhua Piao; Guangchao Sun; Chuanxiang Lv; Yi Jing; Rihua Jin
Journal:  Onco Targets Ther       Date:  2020-02-04       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.